A major redevelopment of Newcastle University's Castle Leazes student village is moving forward, with contractor Bowmer + Kirkland appointed to deliver over 2,000 new affordable rooms, replacing 1960s-era facilities.
Swiss watch and jewelry giant Swatch Group reported a steep decline in full-year profit and revenue, with pre-tax earnings nearly halved as consumer demand softened and operational costs climbed.
As Peloton Interactive prepares to report its Q2 fiscal 2026 results, investors are scrutinizing whether the fitness company's aggressive cost-cutting can finally fuel a sustainable turnaround, despite shares languishing 96% below their peak.
While regional tensions and market volatility capture headlines, a closer look reveals resilient companies with strong fundamentals. Driven by robust earnings and strategic positioning, select stocks in sectors from renewable energy to infrastructure present compelling cases for value-oriented investors navigating the complex landscape of early 2026.
Oil prices pulled back from multi-month highs on Friday amid broad market risk aversion, yet President Trump's intensified focus on Iran continues to inject a significant risk premium into the market, setting Brent crude for its strongest monthly gain in years.
MarineMax's Q4 2025 results surpassed revenue forecasts, driven by robust premium boat sales, but profitability was hampered by industry-wide discounting and cautious consumer spending, leading to a wider-than-expected loss per share.
Levi Strauss & Co. (LEVI) posted stronger-than-expected full-year 2025 results, driven by organic growth and a strategic shift towards direct-to-consumer sales. Yet, with a muted stock performance year-to-date, investors are questioning if the iconic denim maker's transformation story is fully priced in.
After a volatile period that saw shares swing from steep declines to recent gains, investors are scrutinizing whether Weyerhaeuser's current price presents a buying opportunity. A deep dive into valuation metrics reveals a complex picture, with discounted cash flow and P/E ratio analyses telling conflicting stories.
Williams-Sonoma's shares have delivered impressive multi-year gains, but recent valuation metrics present a mixed picture. As the stock hovers around $205, we analyze whether the home goods retailer's price truly reflects its fundamentals or if investors are paying a premium for past performance.
Hubbell Incorporated's stock has surged over 11% in the past month, closing near $498 and prompting a fresh debate among analysts over whether its current price fully reflects future growth potential amidst industry headwinds.
After years of losses, London-listed Buccaneer Energy (LON:BUCE) is projected by analysts to turn its first profit in 2026, marking a potential turning point for the US-focused hydrocarbon explorer.
Real Matters Inc. (TSE: REAL) kicked off its 2026 fiscal year with robust double-digit revenue growth and a return to profitability, defying typical seasonal headwinds. The company's performance was fueled by market share gains, new client launches, and improved operational efficiency across its U.S. and Canadian segments.
Official figures reveal a sharp 26% increase in the annual cost of public sector pensions, now reaching £39bn, with taxpayers covering the bulk of the expense as employer contribution rates rise.
Mitsubishi Corporation and U.S.-based Aethon Energy have announced a strategic global alliance aimed at co-developing projects across liquefied natural gas (LNG), carbon capture, geothermal energy, and digital infrastructure, marking a significant step in the Japanese conglomerate's lower-carbon expansion.
Standex International Corporation reported robust fiscal second-quarter results, with revenue climbing to $221.32 million and net income reaching $2.12 million. The company raised its quarterly dividend by 6.3% and issued an upbeat forecast for the third quarter, reinforcing confidence in its strategic shift toward high-value engineered products.
Blue Owl Capital faces a wave of securities class actions alleging disclosure failures around liquidity and redemptions, casting a shadow over its robust alternative asset management platform. As legal pressures mount, the market weighs solid analyst backing against growing governance concerns, setting the stage for a pivotal earnings report.
The medical technology giant reported double-digit organic sales growth and robust profitability for 2025, driven by record installations of its Mako surgical robots. While projecting continued strength for 2026, management acknowledged incremental tariff pressures but expressed confidence in the company's ability to sustain margin expansion.
Swiss banking giant UBS has initiated coverage on Zai Lab Limited (NASDAQ: ZLAB) with a bullish 'Buy' rating and a $35 price target, highlighting the biopharma firm's strategic pivot from a China-focused player to a burgeoning global innovation platform with a promising proprietary pipeline.
H.C. Wainwright has trimmed its price target on Genmab following mixed Phase 3 results for its lymphoma drug EPKINLY, though maintains a Buy rating, citing precedent and ongoing trials.
Citizens reiterates a 'Market Outperform' rating and $396 price target for BeOne Medicines (ONC), driven by robust Phase 3 trial results in gastric cancer. The firm highlights the company's strong pipeline and cash position as key growth drivers.
